Liu Yi, the former secretary-general of the Chinese Football Association, was sentenced to 11 years' imprisonment in the first instance. According to Xianning Intermediate People's Court, on the morning of December 11, the Intermediate People's Court of Xianning City, Hubei Province publicly pronounced the case of accepting bribes by Liu Yi, the former deputy head of the preparatory group for the change of the Chinese Football Association and the former secretary-general of the Chinese Football Association. The defendant Liu Yi was sentenced to 11 years' imprisonment for accepting bribes and fined RMB 3.6 million. The property obtained from bribery shall be recovered according to law and turned over to the state treasury, and the insufficient part shall continue to be recovered.Japan Life Insurance announced that it would spend $8.2 billion to acquire the life insurance company Resolution Life. On December 11th, Japan Life Insurance Mutual announced that it would spend about $8.2 billion to acquire the remaining 77% shares of the life insurance company Resolution Life. The transaction is expected to be completed in the second half of 2025. On the same day, Japan Life announced that it would acquire the remaining 20% shares of MLC Life Insurance from National Bank of Australia (NAB) and integrate MLC with Resolution Life.Hanwei Technology and others set up a new company in Hubei, including geographic remote sensing information service business. The enterprise search APP shows that recently, Hubei Hanwei Water Technology Co., Ltd. was established, with Zhao Shuai as the legal representative and a registered capital of 10 million yuan. Its business scope includes: intelligent instrument manufacturing; Industrial automatic control system device manufacturing; Research and development of mechanical equipment; Intelligent control system integration; Internet of things equipment sales; Geographic remote sensing information service, etc. Enterprise survey shows that the company is jointly owned by Hanwei Water Technology (Henan) Co., Ltd. and Li Yuhua, a subsidiary of Hanwei Technology.
JPMorgan Chase: The momentum of Xiaomi's electric vehicle will continue to be rated as "overweight". According to a research report published by JPMorgan Chase, Xiaomi Group announced that it will launch the second electric vehicle named Xiaomi Yuqi in the middle of next year, which is an SUV model. The product portfolio of electric vehicle business continues to expand, reflecting that the Group's ability to enter the electric vehicle market is better than market expectations. The delivery target of Xiaomi SU7, the first electric vehicle, has also been raised twice, and the gross profit margin of electric vehicle business has reached a medium-high level in the first two quarters, far exceeding the initial market expectation and only recorded a slight gross profit margin. Motong said that at present, we are waiting for the Group to announce more details about the new car's life, pricing and battery. We believe that the strong sales momentum of SU7, the profitability of the Group's core business and electric vehicle business, and the expectation that new models will be launched in the second half of next year will continue to promote the stock price in the next 6 to 12 months. The positive catalysts in the future include more details or pricing of YU7, further expansion of electric vehicle production capacity, exceeding expectations in core business performance, and large-scale and national consumption stimulus measures introduced by the country in the future.CEO of audi ag: I hope to keep pace with BYD in China. audi ag is in the stage of strategic stability and will enter the growth stage of new energy vehicles from 2026. Audi ag hopes to maintain its leading position in the China market and keep pace with BYD. On December 10th, 2024, Oliver Blume, CEO of German audi ag, made the above remarks in a speech at Tongji University. (Caixin. com)South Korean police conducted a search on the presidential palace, and South Korean police conducted a search on the presidential palace on December 11, local time.
Beijing Stock Option Pioneer Venture Capital Fund was registered and established with a capital contribution of 100 million yuan. According to Tianyancha App, recently, the Stock Option Pioneer Venture Capital Fund (Limited Partnership) was established. The executive partner is Beijing Zhongguancun Capital Fund Management Co., Ltd., with a capital contribution of 100 million yuan. Its business scope is venture capital, and private equity funds are engaged in equity investment, investment management, asset management and other activities. According to the partner information, the fund is jointly funded by Beiyin Wealth Management Co., Ltd., Beijing Zhongguancun Capital Fund Management Co., Ltd. and Beijing Harmony Jiarui Investment Management Co., Ltd.Does the United States or cancel the recognition of the "Sham Liberation Organization" terrorist organization? US officials responded that according to media reports such as CNN, John Kirby, strategic communication coordinator of the US White House National Security Council, said on the 10th local time that the United States has not seriously discussed the cancellation of the Syrian opposition "Sharm Liberation Organization" (HTS) terrorist organization identification. Earlier, some media quoted an anonymous senior official of the US government as saying that the US government did not rule out removing HTS from the list of terrorist organizations recognized by the United States in order to establish closer ties with it. (World Wide Web)Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14